Local cytokine and inflammatory responses to candidate vaginal adjuvants in mice

Vaccine

Volumn 28, Issue 1, 2009, Pages 270-278

  Lindqvist, Madelene ^a   Navabi, Nazanin ^a   Jansson, Marianne ^b   Samuelson, Emma ^a   Sjöling, Åsa ^a   Örndal, Charlotte ^c   Harandi, Ali M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Genital tract immunity; Sexually transmitted infection; Vaccine adjuvant

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CPG OLIGODEOXYNUCLEOTIDE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 5; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE EXPRESSION PROFILING; INFLAMMATION; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TH1 CELL; TOXICITY TESTING; VAGINA; VAGINA EPITHELIUM; VAGINAL INJURY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVAGINAL; ANIMALS; CYTOKINES; EPITHELIUM; FEMALE; GALACTOSYLCERAMIDES; GENE EXPRESSION PROFILING; IMMUNITY, MUCOSAL; LYMPH NODES; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOXICITY TESTS; VAGINA;

EID: 70649099130     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.083     Document Type: Article

References (25)

1. World Health Organization DoRHaR. Global strategy for the prevention and control of sexually transmitted infections: 2006-2015. Breaking the chain of transmission (2007), World Health Organization, Geneva
2. Harandi A.M., Davies G., and Olesen O.F. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev Vaccines 8 March (3) (2009) 293-298
3. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 82 October (5) (2004) 497-505
4. Kwissa M., Kasturi S.P., and Pulendran B. The science of adjuvants. Expert Rev Vaccines 6 October (5) (2007) 673-684
5. Klinman D.M., Klaschik S., Sato T., and Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 61 March (3) (2009) 248-255
6. Vollmer J., and Krieg A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 61 March (3) (2009) 195-204
7. Harandi A.M., Eriksson K., and Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 77 January (2) (2003) 953-962
8. Kwant A., and Rosenthal K.L. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22 August (23-24) (2004) 3098-3104
9. Ashkar A.A., Yao X.D., Gill N., Sajic D., Patrick A.J., and Rosenthal K.L. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J Infect Dis 190 November (10) (2004) 1841-1849
10. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., and Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316 June (5831) (2007) 1628-1632
11. Tengvall S., and Harandi A.M. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice. J Reprod Immunol 78 June (1) (2008) 49-57
12. Tengvall S., O'Hagan D., and Harandi A.M. Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88. Antiviral Res 78 June (3) (2008) 202-214
13. Lindqvist M., Persson J., Thorn K., and Harandi A.M. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol 182 May (10) (2009) 6435-6443
14. Tengvall S., Lundqvist A., Eisenberg R.J., Cohen G.H., and Harandi A.M. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J Virol 80 June (11) (2006) 5283-5291
15. Cone R.A., Hoen T., Wong X., Abusuwwa R., Anderson D.J., and Moench T.R. Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 6 (2006) 90
16. Mestecky J., Moldoveanu Z., and Russell M.W. Immunologic uniqueness of the genital tract: challenge for vaccine development. Am J Reprod Immunol 53 May (5) (2005) 208-214
17. Russell M.W., and Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect 4 May (6) (2002) 667-677
18. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105 July (30) (2008) 10501-10506
19. Iqbal S.M., Ball T.B., Kimani J., Kiama P., Thottingal P., Embree J.E., et al. Elevated T cell counts and RANTES expression in the genital mucosa of HIV-1-resistant Kenyan commercial sex workers. J Infect Dis 192 September (5) (2005) 728-738
20. Hirbod T., Nilsson J., Andersson S., Uberti-Foppa C., Ferrari D., Manghi M., et al. Upregulation of interferon-alpha and RANTES in the cervix of HIV-1-seronegative women with high-risk behavior. J Acquir Immune Defic Syndr 43 October (2) (2006) 137-143
21. Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., and Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270 December (5243) (1995) 1811-1815
22. Schlaepfer E., Audige A., von Beust B., Manolova V., Weber M., Joller H., et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol 78 November (22) (2004) 12344-12354
23. Nowroozalizadeh S., Jansson M., Adamsson J., Lindblad M., Fenyo E.M., Holmgren J., et al. Suppression of HIV replication in vitro by CpG and CpG conjugated to the non toxic B subunit of cholera toxin. Curr HIV Res 6 May (3) (2008) 230-238
24. Wang Y., Abel K., Lantz K., Krieg A.M., McChesney M.B., and Miller C.J. The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the TLR9 agonist, CpG ODN, induce antiviral cytokines and chemokines but do not prevent vaginal transmission of simian immunodeficiency virus when applied intravaginally to rhesus macaques. J Virol 79 November (22) (2005) 14355-14370
25. Fichorova R.N., Tucker L.D., and Anderson D.J. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 184 August (4) (2001) 418-428